Long-acting insulin analogs versus human insulins.
Garg
Satish K
SK
Naik
Ramachandra G
RG
D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy* / Q000191:economics; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000191:economics; D004305:Dose-Response Relationship, Drug; D016527:Drug Costs; D017048:Health Care Costs; D006801:Humans; D007004:Hypoglycemic Agents / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use; D007328:Insulin / Q000031:analogs & derivatives* / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use*; D000069057:Insulin Detemir; D000069036:Insulin Glargine; D007336:Insulin, Isophane / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use*; D049528:Insulin, Long-Acting; D014481:United States; D014486:United States Food and Drug Administration; D015430:Weight Gain / Q000187:drug effects
D007004:Hypoglycemic Agents; D007328:Insulin; D049528:Insulin, Long-Acting; D000069036:Insulin Glargine; D000069057:Insulin Detemir; D007336:Insulin, Isophane